Alveofact
Phase 1Small molecule
Alveofact is one of 8 small molecule programs targeting Neonatal. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Neonatal
#DrugCompanyPhaseTrials
1Fabhalta
Johnson & JohnsonPhase 3
Rayos
RRoxane Laboratories
Phase 3
Ivig
ArgenxPhase 3
Immunoglobulins
CSL BehringPhase 3
Pitressin
AAultman Health Foundation
Phase 1
Pulmicort
SSalix
Phase 1
Alveofact
AAin Shams University
Phase 1
Colostrum
HHadassah Medical Organization
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Neonatal1 trial
Assessment Of Dose-Dependent Immunomodulatory Effect Of Alveofact With or Without Steroisd In Neonatal RDS
Recruiting·—·Phase 1·NCT06367881·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alveofact. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAin Shams University